Xeris Biopharma Holdings, Inc. XERS Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $12.01M+127% | $554K+101% | -$15.64M+75.2% | -$32M+46.3% | -$45.08M+30.0% | ||
| $1.34M+9.8% | $1.31M+7.0% | $1.29M+2.5% | $1.26M-6.3% | $1.22M-16.1% | ||
| $22.06M+15.9% | $22.37M+21.8% | $20.69M+18.0% | $19.81M+49.8% | $19.04M+59.7% | ||
| $48.53M+269% | $28.63M+173% | $8.58M— | -$18.15M— | -$28.68M— | ||
| -$1.01M— | -$696K— | $9.65M— | —— | —— | ||
| —— | —— | —— | —— | -$2.08M— | ||
| $53.21M+1,323% | $39.32M+866% | $32.26M— | $1.58M— | -$4.35M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Xeris Biopharma Holdings, Inc. generate?
- Xeris Biopharma Holdings, Inc. (XERS) generated $48.5M in operating cash flow over the trailing twelve months.
- Where does Xeris Biopharma Holdings, Inc.'s cash flow data come from?
- Every line is extracted from Xeris Biopharma Holdings, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
